Background: Parkinson disease (PD) is a neuropsychiatric disease that is characterized by motor and neuropsychiatric symptoms. Multiple neurotransmitter systems, including the serotonergic system, are involved in the pathophysiology of this disease. The exact role of the serotonergic system in PD is still unclear.
Objective:
To investigate the role of serotonin on specific aspects of cognition, mood, and motor performance in PD.
Methods:
In a double-blind, randomized, placebo-controlled, crossover design, the effects of a nonspecific serotonergic challenge with citalopram, a selective serotonin reuptake inhibitor, and a 5-HT 1a receptor-specific challenge with buspirone on the Visual Verbal Learning Task, Concept Shifting Task, Profile of Mood State Questionnaire, motor section of the Unified Parkinson Disease Rating Scale (section 3), Simple Reaction Time Task, and Finger Precuing Task were studied in 21 PD patients in early stages of their disease and 21 age-, sex-, and education-matched healthy volunteers.
Results:
The serotonergic challenges resulted in similar effects for both groups. No changes of scores on the cognitive tasks (Visual Verbal Learning Task and Concept Shifting Task) were observed. Results of the Profile of Moods State Questionnaire indicated that, at baseline, PD patients scored less than controls on all 5 subscales. Motor performance (measured by reaction time) was negatively affected by the interventions.
Conclusions:
The effects of nonspecific and 5-HT 1a receptorspecific challenging of the serotonergic neurotransmitter system had similar effects in both PD patients and healthy control subjects. These findings indicate that serotonergic function is not impaired in early PD and that serotonin, although involved in the pathophysiology of PD, does not seem to play a direct role in cognition, mood, and motor performance in PD patients, but may be involved in hypokinesia. T he dopaminergic system is not the only system involved in the pathophysiology of Parkinson disease (PD). Other systems, among which is the serotonergic system, are also involved in this process. Degeneration of serotonergic neurons, decreased serotonin content, and alterations in the activities of various serotonin receptor subtypes have all been demonstrated in postmortem studies using neurochemical and autoradiographic techniques. 1Y11 The role and impact of this reduced serotonergic activity in PD, however, remain unclear. From animal research, it is known that serotonin reduces the activity of dopaminergic cells in the substantia nigra pars compacta and reduces striatal dopamine activity release, although there is no consensus with regard to this point. 12Y14 Based on these observations, a compensatory role of reduction in serotonergic activity for the reduced striatal dopamine activity is hypothesized. 12 Additionally, serotonin activity influences several cognitive functions such as memory consolidation and attention shifting.
15Y17
The aim of the present study was to investigate the role of serotonin in cognition, mood, and motor performance in early PD patients by administering either a selective serotonin reuptake inhibitor, citalopram, or a 5-HT 1a agonist, buspirone. Intake of both substances results in an acute elevation of central serotonergic availability. 18, 19 Based on results from earlier investigations and theoretical grounds, 20Y22 we hypothesized that this challenge would have the opposite effect of acute tryptophan depletion (ATD), thus resulting in a positive effect on cognitive performance, more specifically an improvement in delayed recall and delayed recognition of long-term memory (LTM). Because it is reported by Haapiniemi et al that serotonergic levels of PD patients are already lower than the levels of the healthy control subjects, one may expect a greater improvement in PD patients. 23 In addition, based on results from preclinical data, we expected an increased inhibition of striatal dopamine release by elevating the serotonergic availability. It was expected that this would result in a negative effect on aspects of motor performance in PD patients.
METHODS

Subjects
Twenty-one PD patients were included in the study. They were recruited from the neurological outpatient departments of the Maastricht University Hospital and the Atrium Medical Center, Heerlen. All patients were diagnosed with PD, according to the United Kingdom Parkinson's Disease Society Brain Bank criteria. 24 Patients who were diagnosed with any neurological disease other than PD, or with any psychiatric disorder, including depression, as defined by the criteria of the Diagnostic and Statistical Manual (DSM-IV) of the American Psychiatric Association, 25 were excluded from participation. The presence of any psychiatric disorder, notably major depressive disorder, was established in an unstructured psychiatric interview assessing DSM-IV criteria. Other exclusion criteria were the use of psychoactive medication, such as antidepressants and antipsychotics; the use of l-dopa, the dopamine agonist lisuride (because of its known effects on 5-HT 1a activity), and selegeline; the abuse of alcohol or drugs; and dementia, which was operationally defined by a short psychiatric interview checking for the DSM-IV criteria and a score on the Mini-Mental State Examination (MMSE) of less than 23. A prior personal or family history of depression was also considered a ground for exclusion. Participation in the study did not have any influence on the medical treatment patients were receiving. Control subjects were recruited from an existing database of volunteer subjects of the Maastricht Aging Study 26 and individually matched with the PD patients with regard to age, sex, and education level. The same inclusion and exclusion criteria applied to the control subjects, with the exception of PD. The study was approved by the Institutional Review Board of the Maastricht University Hospital. All subjects gave their written consent before participation and received a financial compensation for participating in the study.
Design
The study was conducted according to a double-blind, placebo-controlled, randomized crossover design. Intervention consisted of a placebo, a 40-mg dose of citalopram, or a 30-mg dose of buspirone. The intervention days were at least 7 days apart to rule out any carryover effects.
Intervention
On the 3 test days, subjects received a capsule at 2 time points (0 and 2 h) after having completed the baseline tests in the morning. The capsules contained either a placebo mixture, 40 mg of citalopram (which takes approximately 3.5 h before it reaches its peak level), or 30 mg of buspirone (which takes approximately 1.5 hrs before it reaches its peak level). To maintain blinding of the study, subjects received capsules containing either a placebo, citalopram, or buspirone at 2 time points (0 and 2 h after completing the baseline). Three possible combinations were used. In the first (placebo) condition, subjects received a capsule containing a placebo at both time points. In the second (buspirone) condition, subjects received a placebo containing capsule at the first time point and a capsule containing buspirone at the second time point. The final (citalopram) combination consisted of a capsule containing citalopram at the first time point and a capsule containing the placebo at the second time point. This method of administering the substances enabled us to test the effects of each substance (independent of the time the substances needed to reach peak levels in the brain) at the same time point (3.5 h) after the baseline tests ( Fig. 1 ).
Procedure
Subjects underwent a routine physical examination to rule out any potential physical exclusion criteria. The Hamilton Rating Scale for Depression (HAMD) and the MMSE were obtained to characterize the population and as an exclusion criterion for possible dementia. 27 All patients were staged according to the Hoehn and Yahr staging system. 28 All subjects underwent a training session where all tests used on the test days were practiced to control for learning effects. On the test days, subjects arrived at 9:00 am. Starting the day, a baseline measurement was obtained, after which the subjects received the first capsule. Two hours after the intake of the first capsule, participants took the second capsule. The test measurements were performed again at the point of maximal challenge, which was at 3.5 hours after intake of the first capsule.
Parkinson disease patients were consequently tested at the same time after medication on each test day. Subjects were free only to drink water and eat a light lunch at noon. After finishing the afternoon test session, participants were able to return home.
Outcome Measures
The design of the test battery used in the present experiment was similar to the one used in earlier experiments in our group. 29 The Visual Verbal Learning Task (VVLT) and the Concept Shifting Task (CST) were administered to investigate the effects of the challenges on cognitive functioning, more specifically on learning, memory consolidation, and mental flexibility. To get an impression of the mood status of the subjects, the Profile of Moods State (POMS) Questionnaire was administered. 30 Motor performance was examined using the Unified Parkinson Disease Rating Scale (UPDRS) and 2 reaction time tasks, a Simple Reaction Time task (SRT) and the Finger Precuing Task (FPT). All tasks were obtained at baseline and 3.5 hours after intake of the first capsule.
Visual Verbal Learning Task
The VVLT is an adapted version of the Auditory Verbal Learning Task. 31 Fifteen words are presented 3 times in the same sequence on a computer display. After each of the 3 trials, subjects are asked to recall the words (immediate recall). Twenty-five minutes after the presentation of the first trial, subjects are requested to recall as many words as possible (delayed recall). This is followed by a recognition task consisting of 30 words, of which 15 are previously presented and 15 are new but comparable words. The subject has to respond to the words by answering yes or no, indicating the recognition of the words (delayed recognition). Parallel versions were used at different time points. Outcome variables were the maximum number of words recalled in either of the 3 immediate recall trials as a measure of immediate recall from short-term memory, the number of correctly recalled words on the delayed recall as a measure of retrieval from LTM, and the percentage of correctly recognized words on the recognition task as a measure of LTM storage.
Concept Shifting Task
The CST 32 is derived from the Trail Making Test 33 and is used as a measure for cognitive speed, vasomotor tracking, and cognitive flexibility in various neuropsychological settings (the ability to switch between 2 concepts, eg, letters and numbers). 34, 35 The CST consists of 5 parts. On each sheet, 16 small circles are grouped in a larger circle. In the first 3 parts, the circles contain either numbers (part A), letters (part B), or a combination (part C), all appearing in a random order. The subjects are requested to cross out the items as fast as possible in ascending order in parts A and B, and in part C continuously change between numbers and letters (eg, 1-A, 2-B, 3-C). In the following 2 parts (01 and 02), the 16 empty circles have to be crossed out as fast as possible. Outcome variables were the interference score, obtained by subtracting the mean time needed for parts A and B (in which the total time needed to perform both parts is composed of a cognitive component and a motor speed component) from the time needed for completing part C (in which the total time needed is composed of the cognitive and motor component from parts A and B, but also an interference component because the subject has to change between 2 strategies) as a measure for cognitive flexibility, and part 02 as a motor score without cognitive interference.
Profile of Mood State Questionnaire
The POMS assesses 5 qualities of mood, as follows: depression, anger, fatigue, vigor, and tension. The POMS consists of 32 opposite word pairs divided by a visual analog scale of 100 mm. The POMS was used, instead of depression scales like HAMD or the Beck Depression Inventory, because of its capability to assess mood states at several time points during 1 day and its sensitivity for detecting transient mood fluctuations.
36,37
Unified Parkinson Disease Rating Scale
The UPDRS 38 is a widely used clinical scale rating several aspects of PD, among which are activities of daily living, motor performance, and medication adverse effects. In the present study, only part 3, the part measuring motor performance, was used. 39 
Simple Reaction Time Task
The SRT 40 is used as a measure of speed of information processing. The subject has to react to a target stimulus that is preceded by a warning stimulus. The subject is instructed to focus his/her attention and eyes on an empty square (35 Â 35 mm) on the computer screen and press down a button in front of him using the dominant index finger. A warning cue (a flashing red square) is presented for 1000 milliseconds; and after a variable time interval, the square turns green (the imperative or target stimulus), and the subject has to let go of the button (reaction time; RT) and move to and touch the green square on the computer screen as fast as possible (movement time; MT). The time intervals between offset of the warning signal and onset of the target stimulus ranged from 100 to 3000 milliseconds and were divided into a short (100Y1000 ms), medium (1050Y1500 ms), and long (1550Y3000 ms) interval. Reaction time, MT, and the percentage of errors were used as dependent or outcome variables.
Finger Precuing Task
The finger precuing task is a 4-choice RT task (with the index and middle fingers of both hands operating 4 linearly arrayed response keys), with a precue signal providing information about which fingers to use for responding. That is, the precue reduces the number of possible reactions from 4 to 2 by specifying 2 of 4 possible target locations. Subjects have to respond to a single target stimulus, which appears either after a short-or a long-preparation interval (500 and 2000 ms, respectively) initiated by the appearance of the precue signal, by pressing the corresponding button as fast as possible. 41, 42 Four different precue signals can be distinguished, indicating selective preparation of 2 fingers on 1 hand (hand-cued), the same 2 fingers on 2 hands (finger-cued), different finger on 2 hands (neither-cued), or no selective preparation (uncued). The uncued precue signal provides no advance information about the upcoming target stimulus and associated key press response, so that no selective preparation is possible. This is a necessary control condition because it leaves the basic 4-choice RT unaltered. Reaction time and the percentage of errors were used as outcome variables.
Statistics
This study used a placebo-controlled, double-blind, within-and between-subjects design. Dependent variables of the VVLT, CST, POMS, UPDRS, SRT, and FPT were analyzed using a General Linear Model repeated-measures design. Within-subjects factors were Bintervention[ (placebo vs buspirone vs citalopram) and Btime[ (morning vs afternoon). Regarding the SRT and the FPT, Binterval[ (short, medium, and long regarding the SRT, and short and long with respect to the FPT) was added as a within-subjects factor. BDisease[ (PD vs control subjects) was entered as between-subjects factor. Values of P G 0.05 were considered significant.
RESULTS
Subjects
Twenty-one patients and 21 control subjects matched for sex, age, and education (13 men, and 8 women) were included in the study. Patients had a mean age of 61.2 (T9.1) years and a mean MMSE score of 27.7 (T1.5). Because of individual matching, these values did not differ statistically from the control subjects, who had a mean age of 61.3 (T9.9) and a mean MMSE of 28.5 (T1.4), [t(40) = j0.032, P = 0.974] regarding age and [t(40) = j1.833, P = 0.074] regarding MMSE score. Patients had a low mean HAMD score of 0.81 (T0.9), indicating no clinically relevant signs of depression 37, 43 At the time of testing, 1 patient was treated with anticholinergic medication, 2 patients were treated with an NMDA antagonist, 4 patients were on dopa agonists, and 14 patients were treated with a combination of the medications described above. Patients had a median score of II regarding the Hoehn and Yahr scale (range, IIYIII); 10 patients were in stage 2, 8 patients were in stage 2.5, and 3 patients were in stage 3. Baseline UPDRS part 3 scores for PD patients were 18.05.
Visual Verbal Learning Task
No baseline differences between both groups existed, regarding all outcome variables (immediate recall, delayed recall, and delayed recognition). Using delta scores to correct for baseline performance, results regarding all variables showed no effects of intervention. A significant effect of time of intervention (indicating a decreased performance at the second time point) was observed, using original data (no delta scores), [F(1,78) = 39.45, P G 0.0001; F(1,78) = 120.36, P G 0.0001; F(1,78) = 29.58, P G 0.0001], for immediate recall, delayed recall, and delayed recognition, respectively, regardless of intervention (placebo, buspirone, or citalopram) ( Table 1) .
Concept Shifting Task
There were no main intervention effects and group differences regarding both the interference and motor score of the CST (using delta scores to correct for baseline performance). On baseline, patients were slower than controls [t(39) = 3.37, P = 0.002]. Neither were any time of intervention effects observed.
Profile of Mood State Questionnaire
Regarding the POMS subscales (depression, anger, fatigue, vigor, and tension), a significant baseline difference between patients and control subjects, indicating a lower score for PD patients, existed on all subscales except vigor (all ts G 0.05). Using delta scores to correct for baseline performance, a significant intervention effect was observed for subscales depression [F ( lower scores on the depression, anger, and fatigue subscales than the placebo or citalopram intervention, whereas intervention with citalopram resulted in higher scores. A significant Bintervention by time[ interaction effect was observed for the same 4 variables [F(2,78) = 7.59, P = 0.001; F(2,78) = 7.99, P = 0.001; F(2,78) = 4.93, P = 0.01; F(2,78) = 4.83, P = 0.011, respectively], indicating that the aforementioned treatment effects were present at the last measurement of the respective test day. Although there was a significant between-subjects effect in both the depression and anger subscales [F(1,39)8.67, P = 0.005; F(1,39) = 4.6, P = 0.038, respectively], indicating that PD patients showed lower scores than control subjects, no 3-way interactions between intervention, time, and disease were observed (Table 1 ).
Unified Parkinson Disease Rating Scale
Regarding the UPDRS part 3 (motor symptoms), no effects of intervention were observed. Delta scores were used to correct for baseline performance. Mean scores were 18.05 for the total part 3 at baseline and 18.35 after the intervention.
Simple Reaction Time Task
Concerning RT, there were no baseline group differences for any of the 3 time intervals [t(38) = 1.32, P = 0.196; t(38) = 1.44, P = 0.158; t(38) = 1.66, P = 0.105; short, medium, and long interval, respectively]. Regarding MT, baseline differences (indicating slower movements of PD patients) were observed for all 3 time intervals [t(38) = 3.24, P = 0.002; t(38) = 3.17, P = 0.003; t(38) = 3.16, P = 0.003, respectively]. A near significant Bintervention by interval by disease[ interaction was observed for RT [F(4,152) = 2.18, P = 0.073]. For MT, this 3-way interaction was significant [F(4,152) = 2.72, P = 0.032]. This 3-way interaction indicates that relative to controls, PD patients showed a different (slower) response of MT to buspirone compared with placebo and citalopram intervention, especially for the long interval. Patients benefited more from buspirone than citalopram with regard to the placebo condition. A general effect of time of day for both RT and MT [F(1,38) = 19.24, P = 0.0001; F(1,38) = 38.83, P = 0.0001] was observed for both groups, indicating that performance at the second time point was always slower than at the first time point. The percentage of errors was 1.03% for patients and 0.88% for control subjects. This difference was not significant [t(39) = 1.19, P = 0.24 not significant] (Table 1) .
Finger Precuing Task
Baseline differences, indicating slower performance of the PD patients relative to the control subjects, were observed for all but one (hand-cued for the long interval) variable of the FPT (all ts G 0.05). Results showed a significant 3-way interaction of Binterval by cue by disease[ [F(2,76) = 3.56, P = 0.033], indicating a different response of patients and controls to the different cue conditions as a function of preparation interval (short and long). The difference between patients and controls was present for the short-preparation interval, but not for the long interval. In particular, PD patients had great difficulty using shortduration precues (500 ms), as evidenced by a smaller preparation benefit in the handcued condition and even a preparation cost in the finger-and neither-cued conditions, that is, a longer RT in the finger-and neithercued conditions than the uncued condition (Table 1 ). In contrast, control subjects showed similar precuing benefits for the short-and long-preparation intervals. It was also noted that, overall, precuing benefits were much larger for the easy hand-cues than the more difficult finger-and neithercues. Overall, PD patients made significantly more errors than control subjects, 4.49% and 1.52%, respectively [t(38) = 5.3, P G 0.0001] ( Table 1) .
DISCUSSION
The aim of the present study was to investigate the effects of nonspecific serotonergic and 5-HT 1a receptor-specific challenges on memory processes, cognitive flexibility, motor performance, and mood in PD patients compared with sex-, age-, and educationmatched healthy controls. This is the first study to follow the clinical response to serotonergic challenges in PD patients.
The results only partially corroborated our expectations. Acute challenging of the serotonergic system seems to have no differential effects on memory or cognitive speed and flexibility as measured by the VVLT and CST in both patients and healthy controls. Clear effects of time of day were observed over all intervention conditions, most likely indicating a nonspecific effect of fatigue. Therefore, contrary to the results of ATD studies, in which a clear reduction in cognitive performance, more specifically an impairment in delayed recall and delayed recognition of LTM, was observed, 29, 44 cognitive functioning does not seem to be susceptible to acute increases in serotonergic activity. This is in contrast with the findings of other researchers that suggest that administration of a serotonergic agent enhances LTM in healthy volunteers. 20 This difference can possibly be explained by the age difference of both populations. The population tested in the present study might have baseline age-related memory impairments (present in both the controls and the PD patients). The age of participants in the present study was approximately 60 years, whereas in the study of Harmer et al, it was approximately 40 years. Challenging this aged system might not have the same beneficial effects it has in other, younger groups. The presence of mild forms of a neurodegenerative disease, such as PD, appeared to be of no influence on this finding. The effects on mood as measured by the POMS also indicated that the serotonergic system is still working in a similar way in mild PD patients and healthy controls.
As was expected, the UPDRS scores did not change during each test day nor over the different test days. The UPDRS is not a very sensitive scale for detecting minor changes in motor performance. Motor performance as measured by the SRT and FPT was, however, influenced by the acute serotonergic challenge. The results of the SRT task demonstrate that both the RT and the MT components show a very consistent effect of time of day for both patients and control subjects. Both patients and controls were slower at the second measurement compared with the first (baseline) measurement. The statistically significant 3-way interaction for MT between intervention (placebo, buspirone, and citalopram), disease (PD vs control), and interval (short, medium, and long) shows that PD patients react differently on the interventions over the 3 time intervals. This means that, as can be seen in Table 1 , the effects of buspirone are more beneficial for PD patients than the effects of citalopram with regard to control subjects. In other words, specific targeting of the 5-HT 1a receptor subtype seems to be less disadvantageous for simple motor performance than elevating the general serotonergic levels in the brains of subjects, as is done by administering citalopram. Results of the FPT did not show these intervention-specific effects. In this study, more complex task preparation benefits changed into disadvantages, especially for the PD patients, when the cue conditions became more difficult (the finger-and neithercue conditions). This indicates that, apart from intervention, PD has an effect on the capability of persons to benefit from cues in the execution of more complex motor tasks, especially when fast responses are demanded.
Regarding RT in general, the results described here are complementary to the results of the ATD experiment. After ATD, an improvement in RT responding was found, 29 whereas an impairment was observed after challenging the serotonergic system (as is visible in the positive delta scores). This is interesting because it might indicate that serotonergic mechanisms are at least partially involved in motor processes in both healthy subjects and PD patients. The fact that both groups basically reacted in a similar way indicates that the serotonergic system in the patient group is still functioning the same way as in the control subjects. Because it is known from literature that even in relatively early cases of PD, the serotonergic system shows signs of degeneration, the findings from the present study indicate that although the serotonergic system might not be functioning at its optimal level anymore, it is still able to react properly to functional interventions of the system.
There were a number of limitations to the present study. Patients who participated in the present study were mostly in stage II of the Hoehn and Yahr staging system and had a baseline UPDRS part 3 score of 18.05, indicating that they were relatively early in the disease process. Moreover, PD patients were using various antiparkinsonian medications. Although including only drug-naive patients in a study would be preferred, it is barely possible to include large enough numbers of de novo patients. Therefore, we decided not to exclude patients on medication rigorously, although the use of l-dopa, lisuride, or selegeline was an exclusion criterion. Furthermore, an acute intervention method was used, whereas it might be possible that a prolonged challenge of the serotonergic neurotransmitter system in PD patients might reveal different effects. These facts may have introduced confounders in this study.
CONCLUSIONS
The effects of nonspecific and 5-HT 1a receptor-specific challenging of the serotonergic neurotransmitter system had comparable effects in both PD patients and healthy control subjects. The observed effects were complementary with the results of previous ATD experiments. These findings indicate that serotonergic function is not affected in early PD patients and that serotonin does not seem to play a specific and direct role in the pathophysiology of these patients.
